Hypomethylating agent as first-line treatment for acute myeloid leukemia: Systematic review

被引：0
|
作者：
Jhoputri, Caroline Fricilia [1 ]
Tandokallo, Felicia [1 ]
Kosayuz, Sherina [1 ]
Atmaja, William Surya [1 ]
Kurniawan, Andree [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P12-2
引用
收藏
页码：S1446 / S1446
页数：1
相关论文
共 50 条
  • [41] Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
    J Desoutter
    J Gay
    C Berthon
    L Ades
    B Gruson
    S Geffroy
    I Plantier
    A Marceau
    N Helevaut
    J Fernandes
    M Bemba
    L Stalnikiewicz
    C Frimat
    J Labreuche
    O Nibourel
    C Roumier
    M Figeac
    P Fenaux
    B Quesnel
    A Renneville
    A Duhamel
    C Preudhomme
    Leukemia, 2016, 30 : 1416 - 1418
  • [42] Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use
    Santini, Valeria
    Ossenkoppele, Gert J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 140 : 1 - 7
  • [43] First-line treatment of chronic myeloid leukaemia
    O'Dwyer, Michael
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2010, 1 (01) : 15 - 22
  • [44] Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
    Ilyas, Rimal
    Johnson, Isla McKerrow
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun, V
    Patnaik, Mrinal M. M.
    Pardanani, Animesh
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2022, 140 : 1286 - 1287
  • [45] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [46] Acute myeloid Leukemia Significance of hypomethylating Substances
    Luebbert, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 156 - 156
  • [47] DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
    Metzeler, K. H.
    Walker, A.
    Geyer, S.
    Garzon, R.
    Klisovic, R. B.
    Bloomfield, C. D.
    Blum, W.
    Marcucci, G.
    LEUKEMIA, 2012, 26 (05) : 1106 - 1107
  • [48] DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
    K H Metzeler
    A Walker
    S Geyer
    R Garzon
    R B Klisovic
    C D Bloomfield
    W Blum
    G Marcucci
    Leukemia, 2012, 26 : 1106 - 1107
  • [49] New strategies for the first-line treatment of chronic myeloid leukemia: Can resistance be avoided?
    Snead, Jennifer L.
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 : S107 - S117
  • [50] THE RELATIVE VALUE OF DASATINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKEMIA
    Betegon, L.
    Gilloteau, I
    Martin, P.
    Woolmore, A.
    Oyagueez, I
    VALUE IN HEALTH, 2012, 15 (07) : A420 - A420
12345